Comparative Cost Per Response for four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-To-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
Abstract
Authors
JH Best J Pei